Rokote Laboratories Finland Oy
Rokote Laboratories Finland Oy is a Finnish vaccine development company established in 2020, focusing on developing innovative vaccines including a nasal COVID-19 vaccine. The company collaborates with universities and has received significant funding to advance its vaccine research, aiming to contribute to global health security and vaccine self-sufficiency. It is actively developing a nasal COVID-19 vaccine that aims to provide sterilizing immunity at the virus's entry point, with ongoing clinical trials and a focus on rapid response to virus variants and future pandemics.
Industries
Nr. of Employees
small (1-50)
Products
Second-generation intranasal adenoviral vector vaccine candidate
A nasally administered adenoviral vector vaccine candidate designed to induce both mucosal (nasopharyngeal IgA) and systemic (serum IgG) immunity, with an antigen sequence updated to improve coverage against circulating viral variants and adaptable for future pathogens.
Second-generation intranasal adenoviral vector vaccine candidate
A nasally administered adenoviral vector vaccine candidate designed to induce both mucosal (nasopharyngeal IgA) and systemic (serum IgG) immunity, with an antigen sequence updated to improve coverage against circulating viral variants and adaptable for future pathogens.
Services
Phase I clinical trial design and execution (nasal vaccine)
End-to-end design and conduct of first-in-human nasal vaccine studies including protocol development, dose and administration route assessment (spray vs drops), participant screening, safety monitoring, biological sample collection (serum and mucosal), and integration of remote ePRO data.
CMC development and GMP production coordination
Process development, transfer and coordination of GMP clinical manufacturing with CMOs including MVSS management, batch production oversight and release readiness activities.
Regulatory submission and quality system advisory
Preparation of clinical trial dossiers and regulatory submission materials for national authority and ethics review; advisory support for quality systems and regulatory interactions.
Phase I clinical trial design and execution (nasal vaccine)
End-to-end design and conduct of first-in-human nasal vaccine studies including protocol development, dose and administration route assessment (spray vs drops), participant screening, safety monitoring, biological sample collection (serum and mucosal), and integration of remote ePRO data.
CMC development and GMP production coordination
Process development, transfer and coordination of GMP clinical manufacturing with CMOs including MVSS management, batch production oversight and release readiness activities.
Regulatory submission and quality system advisory
Preparation of clinical trial dossiers and regulatory submission materials for national authority and ethics review; advisory support for quality systems and regulatory interactions.
Expertise Areas
- Vector-based vaccine design (adenoviral)
- Intranasal / mucosal vaccine delivery
- Preclinical and translational evaluation
- Phase I clinical trial conduct and operational design
Key Technologies
- Adenoviral vector platform
- Intranasal mucosal delivery (spray / drops)
- Master viral seed stock (MVSS) and -80 °C cryostorage
- GMP clinical-scale biologics manufacturing